Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Lilibeth Lanceta"'
Publikováno v:
Cells, Vol 10, Iss 7, p 1679 (2021)
Tyrosine kinase inhibitors (TKIs) targeting the kinase domain of the epidermal growth factor receptor (EGFR), such as erlotinib, have dramatically improved clinical outcomes of patients with EGFR-driven non-small cell lung carcinomas (NSCLCs). Howeve
Externí odkaz:
https://doaj.org/article/4965fb7a8acf4f9baf9b6f4ce0194193
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134144 (2015)
Earlier observations indicate that free heme is selectively toxic to cells lacking heme oxygenase-1 (HO-1) but how this enzyme prevents heme toxicity remains unexplained. Here, using A549 (human lung cancer) and immortalized human bronchial epithelia
Externí odkaz:
https://doaj.org/article/47cf34d723a240c7abf3c861b7400a14
Publikováno v:
Cancer Research. 83:P1-13
Breast cancer driven by different hormone receptors, including estrogen receptor (ER+), is responsible for approximately 70-80% of cases among women. While endocrine therapy (ET) of ER+ primary tumors with antiestrogens or aromatase inhibitors is an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96c2b18c90f2ca0b965222f120148d3e
https://doi.org/10.1158/1538-7445.sabcs22-p1-13-18
https://doi.org/10.1158/1538-7445.sabcs22-p1-13-18
Publikováno v:
Cancer Research. 83:6202-6202
Activating mutations of epidermal growth factor receptor (mutEGFR) are established drivers of lung tumor development, aggressiveness, and resistance to targeted therapies. While targeting mutEGFR with small-molecule tyrosine kinase inhibitors (EGFR-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1752dc3d04e75df461bde68c95f31a7
https://doi.org/10.1158/1538-7445.am2023-6202
https://doi.org/10.1158/1538-7445.am2023-6202
Autor:
Xiaohong Li, Jason Chesney, Conor O’Neill, Lilibeth Lanceta, Yoannis Imbert-Fernandez, Eric C. Rouchka, Nadiia Lypova
Publikováno v:
Breast Cancer Research and Treatment
Purpose The management of triple-negative breast cancer (TNBC) remains a significant clinical challenge due to the lack of effective targeted therapies. Inhibitors of the cyclin-dependent kinases 4 and 6 (CDK4/6) are emerging as promising therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b85a45eeec4e5a85df9cf0d00baf335d
https://doi.org/10.1007/s10549-021-06127-5
https://doi.org/10.1007/s10549-021-06127-5
Autor:
Nadiia Lypova, Lilibeth Lanceta, Susan M. Dougherty, Jason A. Chesney, Yoannis Imbert-Fernandez
Publikováno v:
Cancer Research. 82:1772-1772
Breast cancer driven by estrogen receptor (ER) is responsible for approximately 60-70% of cases among women. Selective inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) and ER signaling is now standard-of-care therapy for ER positive (ER+) meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0c02fa22b43f6742f7fc0502d6a80e3
https://doi.org/10.1158/1538-7445.am2022-1772
https://doi.org/10.1158/1538-7445.am2022-1772
Autor:
Xiahong Li, Conor O’Neill, Sabine Waigel, Eric C. Rouchka, Nadiia Lypova, Jorge G. Gomez-Gutierrez, Yoannis Imbert-Fernandez, Lilibeth Lanceta, Jason Chesney
Publikováno v:
Genes
Volume 11
Issue 4
Genes, Vol 11, Iss 467, p 467 (2020)
Volume 11
Issue 4
Genes, Vol 11, Iss 467, p 467 (2020)
Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in estrogen receptor-positive (ER+) breast cancer remains a significant clinical challenge. Efforts to uncover the mechanisms underlying resistance are needed to establish cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d39057cbdfe046309d967e631605f7af
Autor:
Yoannis Imbert-Fernandez, Rodolfo Garza-Morales, Kelly M. McMasters, Lilibeth Lanceta, Jorge G. Gomez-Gutierrez, Alana Gibson, Nadiia Lypova, Stephanie Vega, Jason Chesney
Publikováno v:
Cancers
Volume 11
Issue 5
Cancers, Vol 11, Iss 5, p 684 (2019)
Volume 11
Issue 5
Cancers, Vol 11, Iss 5, p 684 (2019)
While clinical responses to palbociclib have been promising, metastatic breast cancer remains incurable due to the development of resistance. We generated estrogen receptor-positive (ER+) and ER-negative (ER−) cell line models and determined their
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0aa1cd89299c2ebfa4915fbe96d1ed0
http://europepmc.org/articles/PMC6563125
http://europepmc.org/articles/PMC6563125
Publikováno v:
Oncotarget
// Jason Chesney 1,2 , Jennifer Clark 1 , Lilibeth Lanceta 1 , John O. Trent 1,2 and Sucheta Telang 1,2,3 1 Division of Hematology/Oncology, Department of Medicine, J. Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA 2 Depart
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::595244c1c78bebb8fc4e324761617838
http://europepmc.org/articles/PMC4627231
http://europepmc.org/articles/PMC4627231
Autor:
Lilibeth Lanceta, Julie O'Neal, Daniel Alan Kerr, Amy L. Clem, Sucheta Telang, Yoannis Imbert-Fernandez, Robert T. Spaulding, Jason Chesney, Brian F. Clem
Publikováno v:
Journal of Biological Chemistry. 289:9440-9448
Estradiol (E2) administered to estrogen receptor-positive (ER(+)) breast cancer patients stimulates glucose uptake by tumors. Importantly, this E2-induced metabolic flare is predictive of the clinical effectiveness of anti-estrogens and, as a result,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28ad8232372bd26ea3e66bbf283633fa
https://doi.org/10.1074/jbc.m113.529990
https://doi.org/10.1074/jbc.m113.529990